文献速递多重用药老年慢病共病管理

美国老年人阿片类药物与其他中枢神经系统活性药物多重用药

Opioids and Other Central Nervous System-Active Polypharmacy in Older Adults in the United States.
PubMed 文献 · J Am Geriatr Soc · 2017-05-03

基于美国门诊医疗调查2004-2013年数据,分析65岁以上老年人中枢神经系统多重用药(Beers标准定义)模式与趋势。2011-2013年,76.2%的中枢神经系统多重用药就诊包含阿片类药物,61.8%包含苯二氮䓬类;

要点

  • 阿片类药物是近期老年人中枢神经系统多重用药增加的主要驱动因素。
  • 2011-2013年,76.2%的中枢神经系统多重用药就诊含阿片类,61.8%含苯二氮䓬类。

核心结论

  • 在老年人中,阿片类药物的使用似乎是近期全国中枢神经系统多重用药增加的主要驱动因素。
  • 尽管阿片类与苯二氮䓬类共同使用与更高死亡率相关,但它们是老年人中枢神经系统多重用药最常见的贡献者。

研究设计与样本

  • 研究设计为美国国家门诊医疗调查(2004-2013年)的回顾性分析。
  • 研究对象为65岁及以上老年人至门诊医生的就诊记录,样本量N=97,910次就诊。

主要发现

  • 2011-2013年,76.2%的中枢神经系统多重用药就诊包含阿片类药物,61.8%包含苯二氮䓬类。
  • 含苯二氮䓬类的多重用药就诊中66.0%含阿片类,含阿片类的多重用药就诊中53.3%含苯二氮䓬类。
  • 多重用药就诊中,SSRI、NBRA和抗精神病药使用的比值比无变化,TCA使用下降。

关键数值与推荐

  • 中枢神经系统多重用药定义为Beers标准中每类药物中3种或以上中枢神经系统活性药物,包括抗精神病药、苯二氮䓬类、非苯二氮䓬类苯二氮䓬受体激动剂催眠药(NBRA)、三环类抗抑郁药(TCA)、选择性5-羟色胺再摄取抑制剂(SSRI)和阿片类。

临床怎么用

  • 老年医学科医生应关注中枢神经系统多重用药中阿片类与苯二氮䓬类的共处方,因其与死亡率增加相关。
  • 在管理老年人中枢神经系统多重用药时,需评估阿片类和苯二氮䓬类的使用趋势,避免不必要的共处方。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine patterns of and trends in contributions to central nervous system (CNS) polypharmacy, defined by the Beers Criteria as three or more CNS-active medications of each medication class, of adults aged 65 and older seen in U.S. outpatient medical practices. DESIGN: National Ambulatory Medical Care Survey (2004-2013). SETTING: U.S. outpatient medical care. PARTICIPANTS: Visits by older adults to outpatient physicians (N = 97,910). MEASUREMENTS: Visits including three or more CNS medications including antipsychotics, benzodiazepines, nonbenzodiazepine benzodiazepine receptor agonist hypnotics (NBRAs), tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and opioids. The proportion of CNS polypharmacy that each medication class contributed during 2011 to 2013 was determined, and then logistic regression was used to determine trends from 2004 to 2013 in the contribution of individual medication classes to such polypharmacy. RESULTS: Of recent CNS polypharmacy visits, 76.2% included an opioid, and 61.8% included a benzodiazepine; 66.0% of the polypharmacy visits with benzodiazepines included opioids, and 53.3% of the polypharmacy visits with opioids included benzodiazepines. Between 2011 and 2013, opioid and benzodiazepine co-prescribing occurred at approximately 1.50 million visits (95% confidence interval (CI) = 1.23-1.78 million) annually. From 2004 (reference) to 2013, the proportion of polypharmacy visits with opioids rose from 69.6% to 76.2% (adjusted odds ratio = 2.15, 95% CI = 1.19-3.91, P = .01), and the corresponding proportion that included benzodiazepines fell. Of the polypharmacy visits, the odds of SSRI, NBRA, and antipsychotic use were unchanged, and that of TCAs decreased. CONCLUSION: In older adults, opioid use appears to be largely driving the recent national increase in CNS polypharmacy. Although concomitant use of opioids and benzodiazepines is associated with greater mortality, they are the most common contributors to CNS polypharmacy in older adults.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Gerlach LB, Olfson M, Kales HC, et al. Opioids and Other Central Nervous System-Active Polypharmacy in Older Adults in the United States. J Am Geriatr Soc. 2017. PMID: 28467623. doi:10.1111/jgs.14930

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。